Junshi Bio cooperates with Lilly Pharmaceuticals to develop preventive and therapeutic antibody therapies

May 4, Regency Bio and Lilly Pharmaceuticals announced that they had reached an agreement to jointly develop potential preventive and therapeutic antibody therapies for new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.At the beginning of the outbreak of neo-crown pneumonia, Junshi Bio, a Chinese pharmaceutical company focused on the discovery, development and commercialization of innovative therapies, launched the development of treatments for neo-crown pneumonia, one of the first research and development explorations in the industry in this field. Multiple meso-antibodies have been engineered, and pilot antibodies are scheduled to enter clinical phase in the second quarter of this year.“ Since the outbreak of the new crown outbreak, we have been fighting the global epidemic day and night. This agreement with Lilly Pharmaceuticals will help us advance the clinical research of Junshi's new coronary antibodies more quickly around the world," said Dr. Li Ning, CEO of Regency Bio. "At the same time, with Lilly Pharmaceuticals' international reach and operational capabilities, we are expected to reach and treat more patients with new coronary pneumonia for the benefit of a wider range of countries and regions."“ As the number of cases continues to grow globally, there is an urgent need to develop complementary tools to fight the disease," said Daniel Skovronsky, Chief Scientific Officer of Lilly Pharmaceuticals and President of Lilly Research Laboratories. "The data provided by Regency suggests that pilot antibodies may have the appropriate properties to support the validation of their therapeutic use in patients and to explore the potential to protect high-risk individuals from infection. We look forward to working with Regency Bio to quickly start the validation of this potential new therapy in clinical trials. Lillywill obtain exclusive licenses for clinical development, production and commercialization of its products outside of Greater China. Monarch will hold all rights in Greater China.About Resustructive New Coronary Antibody JS016 is a recombinant all-human monoclonal neutralizing antibody, specific to bind to SARS-CoV-2 surface prick protein subject domain, and can effectively block the virus and host cell surface bind ACE2 binding. The project was jointly developed by Junshi Bio and the Institute of Microbiology of the Chinese Academy of Sciences.At the beginning of the outbreak, Junshi Bio quickly launched a research and development program for meso-antibodies to combat the new coronary pneumonia outbreak. Within two months, the company used its excellent process platform to complete the preclinical studies required for IND, antibody process development and production for GLP toxicology research, and antibody GMP production for clinical batches. Reuser Bio and Lilly Pharmaceuticals plan to submit IND applications and initiate clinical studies in the United States in the second quarter of 2020. At the same time, the company is also actively working with the China Drug Administration Drug Review Center to maintain close communication, with a view to submitting IND applications in China as soon as possible. (Sina Pharmaceutical News)